ABSTRACT: The epidemiological and experimental evidence suggests that diabetes can be an independent risk factor for osteoarthritis. The osteoarthritis-like cartilage damage has been shown in streptozotocin-induced diabetic mice. The therapeutic effects of human skeletal muscle-derived progenitor cells (HSMPCs) on diabetic osteoarthritis still remain unclear. Here, we investigated the therapeutic potential of HSMPCs on diabetic knee osteoarthritis. The in vitro chondrogenic ability of HSMPCs was determined by pellet culture assay. Male mice were used to develop the model of streptozotocin-induced type 1 diabetes and its related osteoarthritis. HSMPCs were injected intra-articularly to rescue osteoarthritis. Protein expressions of advanced glycation end-products, cyclooxygenase-2, and type-2 collagen in tissues were determined by immunohistochemistry. The pellet culture assay showed that HSMPCs cultured in differentiation medium for chondrogenesis significantly produced larger pellets with an overproduction of extracellular matrix than in growth medium. In in vivo experiments, intra-articular injection of HSMPCs for 4 weeks significantly prevented the progression of degenerative changes in the cartilage of streptozotocin-induced diabetic mice, including an obvious increase of total articular cartilage thickness and a decrease of fibrous cartilage thickness. HSMPCs transplantation also exerted the decline in advanced glycation end-products and cyclooxygenase-2 protein expression, but increased the type-2 collagen protein expression in streptozotocin-induced osteoarthritic cartilages. Moreover, HSMPCs transplantation also inhibited the increased serum interleukin-6 and matrix metalloproteinase-3 levels in diabetic mice. These results demonstrated for the first time that HSMPCs transplantation ameliorates cartilage degeneration in diabetes-related osteoarthritis mice. These findings suggest that HSMPCs transplantation may apply as a potential therapeutic use of diabetes-related osteoarthritis. ß
Diabetes mellitus is a major health problem of the global population and is the most common metabolic disorder.
1 Type 1 diabetes results approximately 60-80% destruction of the b cells at the time of clinical diagnosis. 2, 3 It has been found that the de novo bone formation during tibial distraction osteogenesis was reduced in a type 1 diabetic mouse model. 4 The increased loss of cartilage during fracture repair has also been observed in streptozotocin (STZ)-induced type 1 diabetic mice. 5 Osteoarthritis (OA) is a degenerative joint disorder with ongoing cartilage destruction and inflammation. Intra-articular injection of stem cells, especially bone marrow derived mesenchymal stem cells, for treatment of knee OA has been developed in animal models and clinical trials. 6 Adult stem cell such as mesenchymal stem cells (MSCs) can be isolated from many organs and tissues, and differentiate into target cells. It has been proposed that skeletal muscle contains the populations of stem/progenitor cells, which can be easily obtained in large quantities through a relatively painless biopsy procedure and is responsible for muscle regeneration. 7 Muscle-derived stem cells have also been found to possess the potential in chondrogenesis and articular cartilage regeneration in vitro and in vivo. 8 Human skeletal myoblasts transplantation has been shown to attenuate hyperglycemia and improve insulin sensitivity in a type 2 diabetic mouse model. 9 Indeed, an association between diabetes and OA has been demonstrated by epidemiological and experimental studies, although there is some controversy. 10, 11 A systematic literature review and meta-analysis indicated that among the 12 studies, 5 showed no association of DM and OA and 7 demonstrated DM as an independent risk factor. 10 Multiple clinical studies have suggested a positive correlation between OA and diabetes due to glucose imbalance and metabolic dysfunction. 12 However, very few studies directly address the animal models for diabetic osteoarthritis. Mooney animals. 13 Our previous study has also shown that a higher OA score with the induction of advanced glycation end products (AGEs) in STZ-induced diabetic mice than in non-diabetic control mice.
14 Moreover, Li et al. have suggested that human skeletal musclederived progenitor cells (HSMPCs) offer a great promise for cell-based therapeutic regeneration through transplantation. 15 However, the therapeutic effect of muscle-derived stem cells on OA in type 1 diabetic model is still unclear. In the present study, we prepared and cultured the HSMPCs and investigated their therapeutic potential on knee OA in a STZinduced type 1 diabetic mouse model.
MATERIALS AND METHODS

Animals
Experiments were undertaken in 5-week-old ICR male mice supplied from the Animal Center of the College of Medicine, National Taiwan University, Taipei, Taiwan. Procedures of animals were performed in accordance with the Guide for the Care and Use of Laboratory Animals 16 and approved by the Institution Animal Care and Use Committee of College of Medicine, National Taiwan University, Taipei, Taiwan. All mice were housed five mice per cage under controlled environmental conditions (22 AE 2˚C and 40-60% relative humidity with a 12 h light and dark cycle) with food and water ad libitum. STZ is known as a chemical for the generation of diabetes.
5,14 A single intraperitoneal injection of 100 mg/kg STZ (Sigma, St. Louis, MO) freshly prepared in sodium citrate buffer (0.05 M, pH 4.5) was used to induce diabetes in mice. Development of diabetic mice was defined by a blood glucose level over 300 mg/dl after STZ injection for 1 week. After STZ injection for 4 weeks, mice were randomly divided into three groups (n ¼ 7/group): (i) non-diabetic control group (control), (ii) diabetic group (STZ) with vehicle control, and (iii) diabetic group with HSMPCs transplantation (STZþ HSMPCs).
HSMPCs Preparation
Human tissue sampling was approved by the National Taiwan University Hospital Institutional Review Board and informed consent from the patient. Primary HSMPCs were isolated from seven rectus muscles of orthopedic surgery patients (mean age, 64 years; range, 34 to 81 years, both male and female) as previously described 17 and characteristics of patients were shown in Table 1 . In brief, the HSMPC suspension was acquired by a serial enzymatic dissociation of the minced muscles in 0.5% type XI collagenase (Sigma) for 1 h, 2.4 IU/ml dispase (Invitrogen, Carlsbad, CA) for 45 min, and 0.2% trypsin-EDTA for 20 min. The cell suspension was through a cell strainer (70 mm) and plated into a collagencoated dish in Ham's F-10 medium supplemented with 20% FBS, 5 ng/ml basic fibroblast growth factor (ProSpec, East Brunswick, NJ), and standard culture antibiotics. The preplate technique was applied to isolate HSMPCs due to different adhesion abilities between fibroblasts and musclederived progenitor cells. 18 After 2 h, the supernatants were re-plated onto another collagen-coated dish for 46 h (passage 1, p1). The adhesive cells were then purified with twice transfers and preplates by the static culture for 30 min and transferring the supernatants onto another collagen-coated dish until 24 h (p2 and p3), and the final passage of HSMPCs (p4) with desmin-positive (as a myogenic progenitor marker) staining were used for the following experiments. 19 Chondrogenic Differentiation of HSMPCs Chondrogenesis of HSMPCs was assessed by pellet culture as previously described with a slight modification. 8 The HSMPCs were resuspended in standard chondrogenic basal medium containing Dulbecco's modified Eagle's medium (DMEM) supplemented with 100 nM dexamethasone (Sigma), 50 mg/ml ascorbate-2-phosphate (Sigma), 40 mg/ml proline (Sigma), 1 mM pyruvate (Gibco, Carlsbad, CA), 10 ng/ml transforming growth factor b3 (TGFb3, Biolegend, San Diego, CA), 100 ng/ml bone morphogenetic protein 4 (BMP-4, PeproTech, Rehovot, Israel) and 1% insulin-transferrin-selenium (ScienCell Research Laboratories, Carlsbad, CA) or DMEM supplemented 20% fetal bovine serum (FBS) only. Pellets were incubated for 21 days at 37˚C in 5% CO 2 , and the medium was changed every 2-3 days.
Assessment of HSMPCs Chondrogenesis
After 21 days of differentiation, the chondroid pellets were fixed in 10% neutral buffered formalin overnight, dehydrated, agarose-cell pellets embedded in paraffin, and sectioned in 4 mm-thick slices. Pellet sections were deparafinized, and placed into acetic acid, Alcian blue solution (Sigma), and counterstained with nuclear fast red solution (Sigma). Pellet sections were also determined the chondrogenic characteristics with Safranin-O staining (Sigma).
Transplantation of HSMPCs
Animals were intra-articularly injected with 10 ml of sterile PBS containing 5 Â 10 5 HSMPCs (mixture of HSMPCs isolated from seven patients) or vehicle under anesthesia using a Hamilton syringe (catalog #80401, Hamilton Company, Reno, NV) and 30-gauge 1/2 needle (BD Biosciences, San Jose, CA) via the patellar ligament into the left knee joint as previously described with a slight modification. 20, 21 The mouse was positioned for lateral entry with the stretching of Unit of amount of tissue harvested: g.
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left hind limb to facilitate the intra-articular injection. After 4 weeks, the live mice were used to osteoarthritis assay.
Histologic Evaluation of Cartilage
The harvested femurs were fixed in paraformaldehyde, decalcified, embedded in paraffin, and prepared as 4 mm thick paraffin sections for Safranin-O/fast green (Sigma) to determine the depth of cartilage and fibrocartilage. The severity of cartilage was graded for cartilage defect healing using the Mankin score system as previously described. 22 Briefly, the articular cartilage impairment was graded according to: (i) structure, graded 0-6, where 0 ¼ normal, 1 ¼ surface irregularities, 2 ¼ pannus and surface irregularities, 3 ¼ clefts to transitional zone, 4 ¼ clefts to radial zone, 5 ¼ clefts to calcified zone, 6 ¼ complete disorganization; (ii)
Immunohistochemistry
Immunohistochemistry was determined as previously described. 23 The sections of paraffin-embedded tissues and pellets were antigen-retrieved by antigen-retrieval solutions (HK057-5 K, BioGenex, Fremont, CA) and blocked by 5% bovine serum albumin (BSA) at room temperature for 1 h. Primary antibodies for advanced glycation end-products (AGEs), cyclooxygenase (COX)-2, and type 2 collagen (Abcam, Cambridge, MA) were applied to sections overnight in a moist chamber at 4˚C. The primary antibody was detected using SuperPicture horseradish peroxidase polymer conjugate and 3,3 0 -Diaminobenzidine (DAB) chromogen (Invitrogen), and subsequently counterstained with haematoxylin. Images were capture with a Nikon D5100 digital camera. Relative optical density of DAB images was semi-quantified using ImageJ analysis software with Immunohistochemistry Image Analysis Tool box (v. 1.48; National Institutes of Health).
Measurement of Interleukin-6 (IL-6) and Matrix Metalloproteinase-3 (MMP-3) Production While mice were sacrificed under anesthesia, sera were collected from blood withdrawal by cardiac puncture for detecting the levels of IL-6 and MMP-3 in the circulation with mouse IL-6 (BioLegend, San Diego, CA) and MMP-3 (ScienCell Research Laboratories, Carlsbad, CA) ELISA kits, respectively, according to the manufacturer's instruction.
Statistics
All results are expressed as Mean AE SEM. Statistical significance was assessed by one way analysis of variance (ANOVA) and Dunnett's test. The significant difference is determined while pvalue is less than 0.05. Statistical analyses were performed using SPSS-16.0 software (IBM SPSS Statistics, Armonk, NY).
RESULTS
Chondrogenic Potential of HSMPCs
We first tested the chondrogenic potential of HSMPCs in vitro using pellet culture. As shown in Figure 1A , HSMPCs cultured in differentiation medium (DM) for chondrogenesis produced significantly larger pellets than that in growth medium (GM). The pellets of HSMPCs produced richer extracellular matrix-like hyaline cartilage determined by Alcian blue staining (Fig. 1B) . Safranin O staining also showed the chondrogenic characterization in pellets (Fig. 1C) . The immunohistochemical staining also showed the marked expression of type-2 collagen in pellets (Fig. 1D ).
Ameliorated Knee OA in STZ-Induced Diabetic Mice by HSMPCs Transplantation
We next investigated the in vivo chondrogenic potential of HSMPCs on STZ-diabetic OA model. Intra-articular injection of HSMPCs for 4 weeks significantly prevented the progression of degenerative changes in the cartilages of STZ-diabetic mice ( Fig. 2A) . HSMPCs transplantation could also significantly reverse the reduction of total articular cartilage thickness (Fig. 2B ) and the elevation of fibrous cartilage thickness (Fig. 2B ) and Mankin OA score (Fig. 2B) in the cartilages of STZ-induced mice. The immunohistochemical staining also showed that HSMPCs transplantation effectively reversed the increased expressions of AGEs and COX-2 and the decreased expression of type-2 collagen in the cartilages of STZ-diabetic mice (Fig. 3) . Moreover, the serum levels of IL-6 and MMP-3 were increased in diabetic mice, which could also be inhibited by HSMPCs transplantation (Fig. 4) .
DISCUSSION
Skeletal muscle is known as the most abundant tissue of the body. Skeletal muscle can regenerate new muscle fibers, when it has been injured or as a consequence of diseases. 24 Muscle regeneration mainly depends on satellite/stem/progenitor cells, which localized between the basal lamina and the muscle fiber membrane. 25 Several animal studies and clinical trials have been reported to investigate the therapeutic potential of intramuscular injection of normal skeletal 
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myoblasts on Duchenne muscular dystrophy [26] [27] [28] ; however, there were some problems to affect the results, including the low survival and migration of donor cells and rejection of the donor cells. 28 On the other hand, MSCs transplantation has been found to attenuate hyperglycemia in clinical trials on type 1 or type 2 diabetes and diabetic animal models. [29] [30] [31] [32] Si et al. further found that infusion of MSCs in a high-fat diet/ STZ-induced diabetic rat model effectively reversed the decreased GLUT4 protein expression and membrane translocation and phosphorylated insulin receptor substrate 1 (IRS-1) and Akt in tissues of skeletal muscle, adipose, and liver. 33 The applicability of MSCs for bone repair and metabolic bone diseases has been reviewed and discussed, 34, 35 and is continually investigating. Moreover, the previous studies have shown that the allogeneic transplantation of human adult MSCs into the knee joints of mice and guinea pigs could cause immune tolerance and improve cartilage injuries of rheumatoid arthritis and osteoarthritis. 36, 37 Our results also revealed that muscle-derived progenitor cells could be applied to prevent the development of OA in a STZ-induced diabetic mouse model.
A clinical and epidemiological survey has suggested that hyperglycemia may be related to the development of OA. 38 An analysis of NHANES III data indicated a positive association between metabolic syndrome and OA, particularly in younger subjects. 39 Nieves-Plaza et al. have found that diabetic patients possess 2.18 fold increased risk of hand or knee OA as compared to non-diabetic subjects in a population of Hispanics from Puerto Rico. 40 A population-based cohort study has also indicated that type 2 diabetes is an independent risk predictor for the development of severe OA. 41 A recent meta-analysis indicated a high frequency of OA in patients with diabetes, showing an association between diabetes and OA. 10 On the other hand, human MSCs are known to possess the ability to differentiate to chondrocytes and have the therapeutic potential for cartilage repair. 42, 43 Chondrogenic potential of murine muscle-derived stem cells in vitro and articular cartilage regeneration in vivo has also been demonstrated. 8 In the present study, we also found the chondrogenic potential of HSMPCs in vitro using pellet culture. We further demonstrated that HSMPCs transplantation effectively attenuated the diabetesrelated OA and enhanced articular cartilage regeneration in a STZ-induced type 1 diabetic mouse model.
For diabetes-related OA, Berenbaum has proposed that increased glucose levels alter the matrix of cartilage through the increase of AGEs formation, which further activates chondrocytes and synoviocytes to induce prodegradative and proinflammatory responses. 11 The AGEs-receptor for AGEs (RAGE) axis has been shown to induce collagen degradation and PPARg downregulation-mediated inflammatory signals in human OA chondrocytes. 44 The glycolaldehydederived intracellular AGEs accumulation has also been found to induce endoplasmic reticulum (ER) stress-mediated apoptosis in mouse chondrocytes. 45 Laiguillon et al. have recently shown that the productions of IL-6 and PGE 2 were greater in human diabetic OA cartilage than in non-diabetic OA cartilage under IL-1b stimulation. 46 Moreover, a recent study indicated that AGEs and COX-2 expressions were up-regulated and collagen II and PPARg expressions were down-regulated in the cartilages of STZ-induced diabetic mice. 14 In the present study, we found that HSMPCs transplantation effectively reversed the increase of cartilage AGEs and COX-2 expressions and collagen degradation and serum IL-6 and MMP-3 levels in STZ-induced type 1 diabetic mice. To date, the chondrogenic potential of several multipotent stem cell sources, including bone marrow-derived stem cells 47 or synovial membrane/fluid-derived stem cells 48 has been investigated. These adult mesenchymal stem cells with differentiating abilities make them attractive for use in the cartilage tissue or other tissue engineering and regenerative medicine. Despite the advanced properties, the limitation may be to yield too few cell numbers of mesenchymal stem cells in the bone marrow or synovial membrane/fluid for tissue engineering applications. 49, 50 However, in the present study, we use HSMPCs as a therapeutic tool to ameliorate the cartilage damage in STZ-induced diabetic mice through their chondrogenic ability and advantageous characteristics of high self-renewal, long-term proliferation capacities, and secretion of trophic factors to promote endogenous tissue repair. [51] [52] [53] What is more, the original tissues used to harvest the HSMPCs could be more easily obtained from healthy muscle tissue biopsies or surgical waste tissue from orthopedic surgery, which may be an important clinical source of mesenchymal stem cells for use in therapeutic applications.
Post-traumatic OA, a progressive and debilitating joint disease, predominantly develops after joint trauma leading to acute post-traumatic arthritis, which represents about 12% of all cases of OA. 54 Joint trauma may trigger the posttraumatic inflammatory response, posttraumatic cartilage cell death, and extracellular matrix degradation by releasing extracellular matrix-degrading enzymes, as well as matrix metalloproteinases. 55 To date, there are no approved pharmacological intervention for post-traumatic OA. Intra-articular delivery of murine bone marrow mesenchymal stem cells has been shown to prevent the development of post-traumatic OA after fracture in mice. 56 In the present study, HSMPCs transplantation effectively inhibited cartilage degradation and serum IL-6 and MMP-3 levels in STZ-induced type 1 diabetic mice. HSMPCs may also possess the therapeutic potential on post-traumatic OA that is worthy of further investigation in the future.
In conclusion, the present study demonstrated for the first time that HSMPCs transplantation effectively reduced hyperglycemia and ameliorated cartilage degeneration in a diabetes-related OA mouse model. These findings suggest that HSMPCs transplantation may apply as a potential therapeutic use for diabetesrelated OA.
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